Spirobarbital

Spirobarbital
Clinical data
Other names5-spiro-(2'-ethyl-3'-5'-dimethyl-cyclopentyl)barbituric acid
ATC code
  • none
Identifiers
IUPAC name
  • 1-ethyl-2,4-dimethyl-7,9-diazaspiro[4.5]decane-6,8,10-trione
CAS Number
UNII
Chemical and physical data
FormulaC12H18N2O3
Molar mass238.287 g·mol−1
3D model (JSmol)
SMILES
  • O=C2NC(=O)NC(=O)C12C(CC)C(C)CC1C
  (verify)

Spirobarbital is a barbiturate derivative developed by Eli Lilly in the 1940s.[1] It has hypnotic and sedative effects, and has a moderate potential for abuse.[2]

References

  1. ↑ US 2561688, Doran WJ, Van Heyningen EM, "Spirobarbituric Acids", issued 24 July 1951, assigned to Eli Lilly and Company
  2. ↑ Isbell H, Chruściel TL (1970). "Dependence liability of "non-narcotic" drugs". Bulletin of the World Health Organization. 43 (Supplement): 5–104. PMID 20718122.


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.